[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2094688B1 - Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. - Google Patents

Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Info

Publication number
ES2094688B1
ES2094688B1 ES09401784A ES9401784A ES2094688B1 ES 2094688 B1 ES2094688 B1 ES 2094688B1 ES 09401784 A ES09401784 A ES 09401784A ES 9401784 A ES9401784 A ES 9401784A ES 2094688 B1 ES2094688 B1 ES 2094688B1
Authority
ES
Spain
Prior art keywords
oil
water
procedure
percent
ophthalmic vehicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
ES09401784A
Other languages
English (en)
Other versions
ES2094688A1 (es
Inventor
Dachs Anna Coll
Perdiguer Nuria Carreras
Valdivia Javier Galan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Cusi SA
Original Assignee
Laboratorios Cusi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Cusi SA filed Critical Laboratorios Cusi SA
Priority to ES09401784A priority Critical patent/ES2094688B1/es
Priority to EP95202053A priority patent/EP0696452B1/en
Priority to AT95202053T priority patent/ATE243995T1/de
Priority to DE69531179T priority patent/DE69531179T2/de
Priority to US08/509,746 priority patent/US5698219A/en
Priority to JP7200760A priority patent/JP2960867B2/ja
Publication of ES2094688A1 publication Critical patent/ES2094688A1/es
Application granted granted Critical
Publication of ES2094688B1 publication Critical patent/ES2094688B1/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

NANOEMULSION DEL TIPO DE ACEITE EN AGUA, UTIL COMO VEHICULO OFTALMICO Y PROCEDIMIENTO PARA SU PREPARACION. LA NANOEMULSION COMPRENDE 0,1-10 POR CIENTO (P/V) DE UN ACEITE; 0,1-10 POR CIENTO (P/V) DE UN TENSIOACTIVO NO IONICO; COMO MAXIMO 0,01 POR CIENTO (P/V) DE CLORURO DE BENZALCONIO; UN FARMACO O UN PRECURSOR O SUSTANCIA ACTIVA; Y OPCIONALMENTE, UNO O VARIOS DE LOS SIGUIENTES COMPONENTES: UN AGENTE ISOTONIZANTE, VISCOSIZANTE O ESTABILIZANTE, UN TAMPON Y/O UN ANTIOXIDANTE EN PROPORCIONES VARIABLES. EL PROCEDIMIENTO COMPRENDE: (A) PREPARAR UNA FASE ACUOSA CONTENIENDO, ENTRE OTROS, UN TENSIOACTIVO NO IONICO; (B) PREPARAR UNA FASE ORGANICA CONTENIENDO DISUELTOS UN ACEITE Y UNA SUSTANCIA ACTIVA EN UN DISOLVENTE ORGANICO MISCIBLE EN AGUA EN TODAS PROPORCIONES; (C) INCORPORAR LA FASE ORGANICA SOBRE LA ACUOSA BAZO MODERADA AGITACION; Y (D) EVAPORAR TOTALMENTE EL DISOLVENTE ORGANICO Y PARTE DEL AGUA HASTA EL VOLUMEN FINAL DESEADO. IMPORTANTES APLICACIONES COMO VEHICULO OFTALMICO EN PREPARADOS DESTINADOS AL TRATAMIENTO DE LOS TRASTORNOS Y ENFERMEDADES OCULARES.
ES09401784A 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. Expired - Fee Related ES2094688B1 (es)

Priority Applications (6)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
EP95202053A EP0696452B1 (en) 1994-08-08 1995-07-26 Nanoemulsion of the oil in water type, useful as an ophthalmic vehicle and process for the preparation thereof
AT95202053T ATE243995T1 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem öl-in-wasser typ, gebrauchbar als ein ophthalmischen vehikel und verfahren zur seiner herstellung
DE69531179T DE69531179T2 (de) 1994-08-08 1995-07-26 Nanoemulsion von dem Öl-in-Wasser Typ, gebrauchbar als ein ophthalmischen Vehikel und Verfahren zur seiner Herstellung
US08/509,746 US5698219A (en) 1994-08-08 1995-07-31 Nanoemulsion of the oil water type, useful as an ophthalmic vehicle and process for the preparation thereof
JP7200760A JP2960867B2 (ja) 1994-08-08 1995-08-07 眼科用ビヒクルとして有用な水中油型ナノエマルジョンおよびその調製法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES09401784A ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Publications (2)

Publication Number Publication Date
ES2094688A1 ES2094688A1 (es) 1997-01-16
ES2094688B1 true ES2094688B1 (es) 1997-08-01

Family

ID=8287242

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09401784A Expired - Fee Related ES2094688B1 (es) 1994-08-08 1994-08-08 Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.

Country Status (6)

Country Link
US (1) US5698219A (es)
EP (1) EP0696452B1 (es)
JP (1) JP2960867B2 (es)
AT (1) ATE243995T1 (es)
DE (1) DE69531179T2 (es)
ES (1) ES2094688B1 (es)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
ES2118033B1 (es) * 1996-02-16 1999-07-01 Bial Ind Farmaceutica S A Formulacion farmaceutica antiinflamatoria.
PL202454B1 (pl) 1997-11-19 2009-06-30 Intendis Gmbh Kompozycja farmaceutyczna zawierająca kwas azelainowy i jej zastosowanie
DE19810655A1 (de) * 1998-03-12 1999-09-16 Univ Eberhard Karls Arzneimittel mit einem Gehalt an Ciclosporin
DE69942205D1 (de) * 1998-08-13 2010-05-12 Cima Labs Inc Microemulsionen als feste dosisformen zur oralen verabreichung
AU5405399A (en) * 1998-09-14 2000-04-03 Vesifact Ag Utilization of nanocells in final culture medium products
GB9823246D0 (en) * 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
FR2787027B1 (fr) * 1998-12-14 2001-01-12 Oreal Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr) * 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr) † 1998-12-17 2001-01-26 Oreal Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr) * 1999-01-05 2001-02-09 Oreal Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
US7767216B2 (en) * 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US8232320B2 (en) * 1999-04-28 2012-07-31 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
WO2000064528A1 (en) 1999-04-28 2000-11-02 Situs Corporation Drug delivery system
US7655252B2 (en) * 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
JP2002154989A (ja) * 2000-11-14 2002-05-28 Lion Corp 眼科用組成物、及び生体粘膜への薬物の滞留性向上組成物
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP2130541A3 (en) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
AU2003900887A0 (en) * 2003-02-27 2003-03-13 Novasel Australia Pty Ltd Poloxamer emulsion preparations
US8802116B2 (en) * 2003-02-27 2014-08-12 Novasel Australia Pty. Ltd. Poloxamer emulsion preparations
WO2005013996A2 (en) 2003-08-07 2005-02-17 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents
CN1878602A (zh) * 2003-11-28 2006-12-13 三菱化学株式会社 有机化合物微粒的制造方法
US8449867B2 (en) 2004-08-31 2013-05-28 Stiefel Research Australia Pty Ltd Microemulsion and sub-micron emulsion process and compositions
EP2438910A1 (en) * 2004-08-31 2012-04-11 Stiefel Research Australia Pty Ltd Microemulsion & sub-micron emulsion process & compositions
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
EP1809237B1 (en) * 2004-11-09 2008-12-31 Novagali Pharma SA Ophthalmic oil-in-water type emulsion with stable positive zeta potential
US20080145430A1 (en) * 2004-12-08 2008-06-19 Santipharp Panmai Ophthalmic Nanoparticulate Formulation Of A Cyclooxygenase-2 Selective Inhibitor
WO2007000842A1 (ja) * 2005-06-29 2007-01-04 Mitsubishi Chemical Corporation 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
CA2618974C (en) * 2005-08-09 2014-01-28 Nanobio Corporation Nanoemulsion compositions having anti-inflammatory activity
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US10137083B2 (en) * 2006-03-07 2018-11-27 SGN Nanopharma Inc Ophthalmic preparations
US11311477B2 (en) 2006-03-07 2022-04-26 Sgn Nanopharma Inc. Ophthalmic preparations
US20070264349A1 (en) * 2006-03-07 2007-11-15 Novavax, Inc. Nano-structured compositions and methods of making and using the same
PT1864668E (pt) 2006-06-01 2013-02-26 Novagali Pharma Sa Utilização de pró-fármacos para administração ocular intravítrea
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
EP2078026B1 (en) 2006-11-21 2012-01-04 Rigel Pharmaceuticals, Inc. Prodrug salts of 2, 4-pyrimidinediamine compounds and their uses
CN101848702B (zh) 2006-12-01 2013-07-17 安特里奥公司 两亲实体纳米粒子
ES2796116T3 (es) 2006-12-21 2020-11-25 Santen Sas Procedimiento para la fabricación de emulsiones oftálmicas de tipo aceite en agua
US20080201330A1 (en) * 2007-02-16 2008-08-21 Microsoft Corporation Software repositories
US8145673B2 (en) * 2007-02-16 2012-03-27 Microsoft Corporation Easily queriable software repositories
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
DE602007009213D1 (de) * 2007-07-09 2010-10-28 Novagali Pharma Sa är Ammoniumhalogenide
CA2730221C (en) * 2007-07-09 2016-02-02 Novagali Pharma Sa Oil in water emulsion comprising nsaids and quaternary ammonium halides
US8512687B2 (en) 2007-07-09 2013-08-20 Novagali Pharma Sa Oil in water emulsion comprising NSAIDs and quaternary ammonium halides
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
WO2009067734A1 (en) * 2007-11-28 2009-06-04 Commonwealth Scientific And Industrial Research Organisation Nanoemulsions
EP2564853B1 (en) * 2007-12-04 2019-02-27 Santen SAS Compositions comprising corticosteroid prodrug such as dexamethasone palmitate for the treatment of eye disorders
AU2008350907A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
EP2271314A4 (en) * 2008-03-28 2013-12-25 Univ Massachusetts COMPOSITIONS AND METHODS FOR PREPARING NANOEMULSIONS
KR20110010788A (ko) * 2008-05-28 2011-02-07 알콘 리서치, 리미티드 자기보존 에멀젼
CA2743904A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
PE20110924A1 (es) 2009-01-23 2011-12-24 Rigel Pharmaceuticals Inc Derivados de 2, 4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
AU2010210600B2 (en) 2009-02-06 2016-07-14 C3 Jian, Inc. Calcium-binding agents induce hair growth and/or nail growth
CN102405044A (zh) 2009-02-06 2012-04-04 南加利福尼亚大学 含有单萜的治疗组合物
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
US9017725B2 (en) 2009-06-09 2015-04-28 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
EP2459195A1 (en) 2009-07-28 2012-06-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
WO2011103510A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation Dha ester emulsions
US20110200645A1 (en) * 2010-02-18 2011-08-18 Martek Biosciences Corporation DHA Free Fatty Acid Emulsions
US20110206741A1 (en) * 2010-02-18 2011-08-25 Martek Biosciences Corporation DHA Triglyceride Emulsions
CN102892289B (zh) 2010-03-03 2015-03-25 尼昂克技术公司 包含单萜的药物组合物
SI2563771T1 (sl) 2010-04-24 2016-05-31 Viamet Pharmaceuticals, Inc. Spojine inhibitorjev metaloencimov
BR112013001632B1 (pt) 2010-07-28 2021-05-25 Rigel Pharmaceuticals composto, composição farmacêutica, e, método de fabricar um composto
EP2883543B1 (en) 2010-08-27 2016-11-16 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol carbamates
US20160038600A1 (en) 2012-08-03 2016-02-11 Neonc Technologies Inc. Pharmaceutical compositions comprising poh derivatives
JP5921560B2 (ja) 2010-10-28 2016-05-24 イノクリン ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害化合物
KR101848077B1 (ko) 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
US9987226B2 (en) * 2010-12-10 2018-06-05 Ns Technologies Pty Ltd Methods for forming miniemulsions and use thereof for delivering bioactive agents
US8669274B2 (en) 2010-12-13 2014-03-11 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103517892B (zh) 2010-12-17 2016-01-27 尼昂克技术公司 使用异紫苏醇的方法和装置
US9169182B2 (en) 2011-02-25 2015-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chrysophaentin analogs that inhibit FtsZ protein
CN109517897A (zh) 2011-04-28 2019-03-26 南加利福尼亚大学 人类髓源抑制性细胞癌症标记
AU2012273103B2 (en) 2011-06-19 2017-04-20 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
WO2012177608A1 (en) 2011-06-19 2012-12-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
EA201490052A1 (ru) 2011-06-23 2014-04-30 Вайамет Фармасьютикалс, Инк. Соединения, ингибирующие металлоферменты
EP2567689A1 (en) 2011-09-12 2013-03-13 Visiotact Pharma Ophthtalmic compositions comprising prostaglandin F2 alpha derivatives and hyaluronic acid
PT2788343T (pt) 2011-12-11 2018-06-01 Viamet Pharmaceuticals Nc Inc Compostos inibidores de metaloenzimas
WO2013093823A2 (en) 2011-12-20 2013-06-27 Vyome Biosciences Pvt Ltd Topical oil composition for the treatment of fungal infections
CN104136427B (zh) 2012-01-20 2017-03-01 威尔金制药有限公司 金属酶抑制剂化合物
US9278132B2 (en) * 2012-02-13 2016-03-08 Bausch & Lomb Incorporated Ophthalmic pharmaceutical compositions and methods of making and using same
CA2867891C (en) 2012-03-19 2021-09-14 Buck Institute For Research On Aging App specific bace inhibitors (asbis) and uses thereof
US8877967B2 (en) 2012-03-23 2014-11-04 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
ES2769578T3 (es) 2013-02-12 2020-06-26 Buck Inst Res Aging Hidantoínas que modulan el procesamiento de APP mediado por BACE
AU2014252157B2 (en) * 2013-04-12 2017-05-11 Vyome Therapeutics Limited Composition and formulation of antimicrobial agents, processes thereof and methods for treating microbial infections
JP2014028865A (ja) * 2013-11-11 2014-02-13 Santen Sas 眼科用水中油型乳剤を製造する方法
US10251837B2 (en) * 2014-02-14 2019-04-09 Jingjun Huang Compositions for nanoemulsion delivery systems
WO2015186040A1 (en) * 2014-06-02 2015-12-10 Sun Pharmaceutical Industries Limited Stable nanoemulsion composition
US11324800B2 (en) 2015-01-15 2022-05-10 Wellspring Ophthalmics, Inc. Aqueous suspensions of cyclosporin
US20200237859A1 (en) 2019-01-25 2020-07-30 Newport Research, Inc. Aqueous suspensions of cyclosporin
WO2016130800A2 (en) 2015-02-12 2016-08-18 Neonc Technologies Inc. Pharmaceutical compositions comprising perillyl alcohol derivatives
JP6994454B2 (ja) 2015-08-04 2022-01-14 ライジェル ファーマシューティカルズ， インコーポレイテッド ベンズアゾール化合物ならびに該化合物の作製方法および使用方法
JP6803923B2 (ja) 2015-12-30 2020-12-23 エヌキューピー １５９８，リミテッド 金属酵素阻害化合物
US10710983B2 (en) 2016-06-27 2020-07-14 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
CN113244291A (zh) * 2016-08-19 2021-08-13 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法以及用于治疗人眼的组合物
JP7170634B2 (ja) 2016-10-26 2022-11-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
CN115531387A (zh) 2016-10-26 2022-12-30 里格尔药品股份有限公司 用作irak抑制剂的吡唑酰胺化合物
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3547836B1 (en) 2016-11-30 2024-08-21 University of Southern California A perillyl alcohol-3 bromopyruvate conjugate and methods of treating cancer
RU2764666C2 (ru) 2016-12-29 2022-01-19 Селенити Терапьютикс (Бермуда), Лтд. Соединения, ингибирующие металлоферменты
WO2018125799A2 (en) 2016-12-29 2018-07-05 Viamet Pharmaceuticals (Bermuda), Ltd. Metalloenzyme inhibitor compounds
JP7183164B2 (ja) 2017-01-05 2022-12-05 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｐａｃ１受容体作動薬（ｍａｘｃａｐ）及びその用途
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CA3068305A1 (en) 2017-06-29 2019-01-03 Rigel Pharmaceuticals, Inc. Kinase inhibitors and methods for making and using
EP3668474A4 (en) 2017-08-18 2021-05-26 Akrivista, LLC METHODS OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
US11414450B1 (en) 2017-08-28 2022-08-16 Revagenix, Inc. Aminoglycosides and uses thereof
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
CN111936125A (zh) 2018-02-08 2020-11-13 尼昂克技术公司 穿透血脑屏障的方法
WO2019194858A1 (en) 2018-04-03 2019-10-10 Achaogen, Inc. Modular synthesis of aminoglycosides
IL278417B2 (en) 2018-05-03 2024-05-01 Rigel Pharmaceuticals Inc RIP1 inhibitory compounds and methods for their preparation and use
JP7379467B2 (ja) 2018-05-03 2023-11-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｒｉｐ１阻害剤化合物並びにそれを製造及び使用するための方法
CA3115664A1 (en) * 2018-08-29 2020-03-05 Ocugen, Inc. Ophthalmic compositions and methods of use
US20220000880A1 (en) 2018-11-01 2022-01-06 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
KR102643707B1 (ko) 2019-01-22 2024-03-04 에오비안 파마슈티컬스, 인크. Mtorc 조절제 및 이의 용도
WO2020243612A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
GB201909358D0 (en) * 2019-06-28 2019-08-14 Smoukov Stoyan K Oil-in-water emulsion of nano-sized self-emulsified particulates
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
CN114286679A (zh) 2019-08-14 2022-04-05 里格尔药品股份有限公司 阻断或改善细胞因子释放综合征的方法
WO2021041898A1 (en) 2019-08-30 2021-03-04 Rigel Pharmaceuticals, Inc. Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulations
BR112022002580A2 (pt) 2019-09-06 2022-07-19 Rigel Pharmaceuticals Inc Compostos inibitórios de rip1 e métodos para preparação e uso dos mesmos
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
KR20220079919A (ko) 2019-11-07 2022-06-14 리겔 파마슈티칼스, 인크. 헤테로시클릭 rip1 억제 화합물
US20220288047A1 (en) 2021-03-03 2022-09-15 Rigel Pharmaceuticals, Inc. Method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
PL438501A1 (pl) * 2021-07-16 2023-01-23 Uniwersytet Medyczny Im.Piastów Śląskich We Wrocławiu Kompozycja w postaci nanoemulsji na bazie oleju roślinnego, kompozycja wielofazowa oraz sposób wytwarzania tych kompozycji
AU2023228405A1 (en) 2022-03-04 2024-10-10 Revagenix, Inc. Broad spectrum aminoglycosides and uses thereof
WO2023183377A1 (en) 2022-03-23 2023-09-28 Rigel Pharmaceuticals, Inc. Pyrimid-2-yl-pyrazole compounds as irak inhibitors
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2832721A (en) * 1956-07-23 1958-04-29 Merck & Co Inc Vitamin emulsions
JPH0647533B2 (ja) * 1984-08-10 1994-06-22 裕 水島 ４−ビフエニリル酢酸系化合物含有脂肪乳剤
JPS62270521A (ja) * 1986-05-16 1987-11-24 Green Cross Corp:The フルルビプロフエン眼投与製剤
US5171566A (en) 1986-05-16 1992-12-15 The Green Cross Corporation Flurbiprofen derivative ophthalmic preparation
IE873504L (en) * 1987-01-28 1988-07-28 Harvard College Stabilized ophthalmic compositions
US5342625A (en) * 1988-09-16 1994-08-30 Sandoz Ltd. Pharmaceutical compositions comprising cyclosporins
CA2083711A1 (en) * 1990-06-08 1991-12-09 Seang H. Yiv Process for preparing microemulsion
CA2052950A1 (en) * 1990-10-10 1992-04-11 David P. Evitts Aqueous ophthalmic microemulsions of tepoxalin
IL98747A0 (en) 1991-07-05 1992-07-15 Yissum Res Dev Co Ophthalmic compositions
IL101007A (en) * 1992-02-18 1997-08-14 Pharmos Ltd Dry stable compositions prepared by lyophilization
CA2142103C (en) * 1992-08-28 2003-07-08 Haim Aviv Submicron emulsions as ocular drug delivery vehicles

Also Published As

Publication number Publication date
JPH0899867A (ja) 1996-04-16
ATE243995T1 (de) 2003-07-15
EP0696452A1 (en) 1996-02-14
DE69531179T2 (de) 2004-04-15
EP0696452B1 (en) 2003-07-02
JP2960867B2 (ja) 1999-10-12
US5698219A (en) 1997-12-16
ES2094688A1 (es) 1997-01-16
DE69531179D1 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
ES2094688B1 (es) Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
ES2200008T3 (es) Formulacion espumable y espuma.
MX173607B (es) Antitranspirante cristalino y metodo para su preparacion
ES2443548T3 (es) Composiciones farmacéuticas acuosas que contienen complejos de borato-poliol
KR890000098A (ko) 세포 및 조직 수복제
ATE537812T1 (de) Zusammensetzungen und verfahren zur verbesserten verabreichung hydrophober therapeutischer wirkstoffe
BR0108449A (pt) Formulações de pasta aperfeiçoada
ES2530774T3 (es) Método para producir partículas secas
ES2134359T3 (es) Composiciones viscoelasticas de compuestos organicos fluorados.
PE63998A1 (es) Composiciones anti-fungosas
RU94046143A (ru) Фармацевтическая композиция для лечения глаукомы
KR960700039A (ko) β-시클로덱스트린 유도체 및 탄산 탈수효소 저해제로 이루어진 안과용 국소 투여 조성물(Topical Compositions for the Eye Comprising a β-cyclodextrin Derivative and a Carbonic Anhydrase Inhibitor)
GT200200076A (es) Producto cosmetico de dos fases aplicable con una bola
ES2011232T3 (es) Composiciones farmaceuticas de piroxicam en soluciones acuosas y procedimiento para su preparacion.
BRPI0709985A2 (pt) composição de brimonidina e timolol
ES2775825T3 (es) Dapsona para tratar la rosácea
ES2304913T1 (es) Composiciones farmaceuticas re-epitelizantes que contienen goma de xantano.
ES2054690T3 (es) Uso farmaceutico de extractos de gramineas.
AR041936A1 (es) Formulacion micelar acuosa que comprende un primer agente activo seleccionado de bencimidazoles insolubles en agua, salicilanilidas y derivados activos o sales de los mismos en combinacion con un segundo agente activo seleccionado de lactonas macrociclicas o derivados activos o sales de las mismas y
PE20000158A1 (es) Formulacion insecticida acuosa para vertirse
KR940006575A (ko) 증가된 안내압 치료를 위한 안구 국소 투여용 약제학적 조성물
JP4844706B2 (ja) 眼科用組成物
ES2208434T3 (es) Uso de la ubiquinona q10 para un tratamiento local y para la prevencion de las patologias oftamologicas posquirurgicas.
SI21079B (sl) Formulacija, ki povecuje mobilizacijo
GT200000224A (es) Composicion para el tratamiento de tejidos dañados.

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 19970116

Kind code of ref document: A1

Effective date: 19970116

FD2A Announcement of lapse in spain

Effective date: 20180806